Response Letters: Author Replies

Reply – Clinical Spectrum of DrugInduced Movement Disorders: A Study of 97 Patients

Authors: {'first_name': 'Anjali', 'last_name': 'Chouksey'},{'first_name': 'Sanjay', 'last_name': 'Pandey'}
Keywords: Drug-induced movement disorderDopamine receptor blocker agentsTardive syndromes 
 Accepted on 29 Nov 2020            Submitted on 27 Nov 2020

We thank Gupta and colleagues for their comments on our recently published article on drug-induced movement disorders (DIMDs) [1, 2]. We will like to clarify certain relevant points raised by them. Firstly, the most common mechanism of drug-induced tremors is the enhancement of physiological tremor, which is low-amplitude, high-frequency tremor at rest and during the action that is often asymptomatic [3]. A temporal relation to the start of pharmacotherapy and dose-response relation is useful in making the diagnosis of drug-induced or drug- exacerbated tremor. Nevertheless, we agree with Gupta et al that sometimes it can be challenging to differentiate drug-induced tremor from essential tremor, however, lack of tremor progression after stoppage of the suspected drug can give a clue to drug-induced etiology. Secondly, the most common antiepileptic drugs (AEDs) to cause movement disorder in our study were valproate, phenytoin, and levetiracetam. We agree with the comments of Gupta et al that the levetiracetam induced dyskinesia has rarely been described in the literature [4]. However, 22 % of patients of AED associated DIMD in our study were on polytherapy, including other AEDs or dopamine receptor blocking agents (DRBA). In such patients, the contribution of each drug in the pathogenesis of DIMD is difficult to access. Thirdly, Gupta et al pointed out the entity called tardive tremor, which occurs after long-term use of neuroleptic medication; however, this category is not included in the DSM-5 criteria of DIMD. We also had five patients in our study who developed tremor after the intake of neuroleptics. Finally, we agree with the comments of Gupta et al that there is a need to raise awareness among the emergency room physicians and general practitioners about movement disorders as a possible side effect of different pharmacological agents including DRBAs and non-DRBAs. Thus, our intent behind this study was to call the attention of physicians towards DIMD patients in whom the cessation of medication can help to ameliorate the involuntary movement and avoid unnecessary workup.

Ethics and Consent

We confirm that we have read the Journal’s position on issues involved in the ethical publication and affirm that this work is consistent with those guidelines. We also confirm that the patient has given written informed consent for the publication of his video.

Competing Interests

The authors have no competing interests to declare.

Author Contributions

Dr. Anjali Chouksey contributed in data collection and manuscript preparation.

Dr. Sanjay Pandey contributed in manuscript preparation, review and critique.

  1. Research project: A. Conception, B. Organization, C. Execution;
  2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
  3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique.

Dr. Anjali Chouksey: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B, 3C

Dr. Sanjay Pandey: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B, 3C


  1. Response Letter: Clinical Spectrum of Drug-Induced Movement Disorders: A Study of 97 Patients. Tremor and Other Hyperkinetic Movements. 

  2. Chouksey A, Pandey S. Clinical Spectrum of Drug-Induced Movement Disorders: A Study of 97 Patients. Tremor and Other Hyperkinetic Movements. 2020; 10: 48. DOI: 

  3. Morgan JC, Kurek JA, Davis JL, Sethi KD. Insights into pathophysiology from medication-induced tremor. Tremor Other Hyperkinet Mov. 2017; 7. DOI: 

  4. Yim S, Choi YH, Heo K, et al. A case of dyskinesia after levetiracetam administration. BMC Neurol. 2019; 19: 292. DOI: